CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells

Guo, Zhaoming; Liu, Ye; Zhou, Hao; Zheng, Keyan; Wang, Dong; Jia, Mingli; Xu, Pengcheng; Ma, Kun; Cui, Chang-Hao; Wang, Li

doi:10.1016/j.colsurfb.2019.110546

Cited by 32 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, dendritic cells also express SIRPα, whether aCD47@CaCO 3 promoted dendritic cell‐based phagocytosis of tumor cells to facilitate dendritic cell maturation in vivo remains to be determined. Moreover, a recent study demonstrated that CD47‐targeted bismuth selenide nanoparticles (Ab‐PEG‐Bi 2 Se 3 ) [ 108 ] can increase phagocytosis of tumor cells by macrophages with inhibited crosstalk between CD47 and SIRPα. Meanwhile, Ab‐PEG‐Bi 2 Se 3 served as a nanoagent for photothermal therapy due to its excellent photothermal performance.…”

Section: Opportunity For Nanomedicine Interventionmentioning

confidence: 99%

Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention

Zhou

Liu

Huang

2020

Adv Funct Materials

View full text Add to dashboard Cite

Macrophages are one of the most abundant non‐malignant cells in the tumor microenvironment, playing critical roles in mediating tumor immunity. As important innate immune cells, macrophages possess the potential to engulf tumor cells and present tumor‐specific antigens for adaptive antitumor immunity induction, leading to growing interest in targeting macrophage phagocytosis for cancer immunotherapy. Nevertheless, live tumor cells have evolved to evade phagocytosis by macrophages via the extensive expression of anti‐phagocytic molecules, such as CD47. In addition, macrophages also rapidly recognize and engulf apoptotic cells (efferocytosis) in the tumor microenvironment, which inhibits inflammatory responses and facilitates immune escape of tumor cells. Thus, intervention of macrophage phagocytosis by blocking anti‐phagocytic signals on live tumor cells or inhibiting tumor efferocytosis presents a promising strategy for the development of cancer immunotherapies. Here, the regulation of macrophage‐mediated tumor cell phagocytosis is first summarized, followed by an overview of strategies targeting macrophage phagocytosis for the development of antitumor therapies. Given the potential off‐target effects associated with the administration of traditional therapeutics (for example, monoclonal antibodies and small molecule inhibitors), the opportunity for nanomedicine in macrophage phagocytosis intervention is highlighted.

show abstract

Section: Opportunity For Nanomedicine Interventionmentioning

confidence: 99%

Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention

Zhou

Liu

Huang

2020

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…For qualitative analysis, macrophages stained with an APC-conjugated anti-CD14 antibody were seeded into 6-well plates with 8 × 10 4 cells/well in 0.4 ml of medium and cultured for 18 h. Then, the cells were pretreated with concentrations of 0, 2, 4 and 8 nM bullatacin for 24 h. After treatment, the PE-conjugated BioParticles or 4 × 10 4 HT-29 cells labelled with CFSE were added to 6-well plates and incubated for 24 h [ 28 ]. After the BioParticles or tumour cells were phagocytosed by macrophage, the fluorescence in the macrophage was measured by flow cytometry.…”

Section: Methodsmentioning

confidence: 99%

Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticulum chaperones

Fan

Shen

et al. 2021

J Inflamm

View full text Add to dashboard Cite

Background It is well accepted that the immune system efficiently contributes to positive outcomes of chemotherapeutic cancer treatment by activating immunogenic cell death (ICD). However, only a limited number of ICD-inducing compounds are well characterized at present; therefore, identification of novel ICD inducers is urgently needed for cancer drug discovery, and the need is becoming increasingly urgent. Methods Herein, we assessed the antitumour activity of bullatacin by MTS assay and apoptosis assay. ICD biomarkers, such as calreticulin (CRT), high-mobility group protein B1 (HMGB-1), heat shock protein (HSP)70, HSP90 and ATP, were assessed by Western blotting, ELISA and flow cytometry. Western blot and qPCR assays were performed to explore the underlying mechanisms of bullatacin-induced ICD. Flow cytometry was used to detect macrophage phagocytosis. Results First, bullatacin induced apoptosis in both SW480 cells and HT-29 cells in a time-dependent manner at 10 nM, as assessed by flow cytometry. Moreover, Western blot and flow cytometry assays showed that CRT and HSP90 (biomarkers of early ICD) significantly accumulated on the cell membrane surface after approximately 6 h of treatment with bullatacin. In addition, ELISAs and Western blot assays showed that the second set of hallmarks required for ICD (HMGB1, HSP70 and HSP90) were released in the conditioned media of both SW480 and HT-29 cells after 36 h of treatment. Furthermore, qPCR and Western blot assays indicated that bullatacin triggered ICD via activation of the endoplasmic reticulum stress (ERS) signalling pathway. Finally, bullatacin promoted macrophage phagocytosis. Conclusion This study documents that bullatacin, a novel ICD inducer, triggers immunogenic tumour cell death by activating ERS even at a relatively low concentration in vitro.

show abstract

“…82 Zhaoming Guo et al developed CD47-targeted Ab-PEG-Bi2Se3 were developed, which can specifically block the crosstalk between CD47 and SIRP α, enhance the phagocytosis of macrophages to tumor cells, and achieve improved PTT. 83 Recent reports have found that ICD inducers can kill tumor cells, convert them into vaccines, and release immunostimulatory vaccines. The success of anticancer vaccination is related to the immunogenicity potential of dead/dead cells as an antigen/auxiliary source.…”

Section: Immunogenic Cell Death (Icd)mentioning

confidence: 99%

<p>Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles</p>

Hou

Yang

Liu

et al. 2020

IJN

242

View full text Add to dashboard Cite

The ultimate goal of phototherapy based on nanoparticles, such as photothermal therapy (PTT) which generates heat and photodynamic therapy (PDT) which not only generates reactive oxygen species (ROS) but also induces a variety of anti-tumor immunity, is to kill tumors. In addition, due to strong efficacy in clinical treatment with minimal invasion and negligible side effects, it has received extensive attention and research in recent years. In this paper, the generations of nanomaterials in PTT and PDT are described separately. In clinical application, according to the different combination pathway of nanoparticles, it can be used to treat different diseases such as tumors, melanoma, rheumatoid and so on. In this paper, the mechanism of pathological treatment is described in detail in terms of inducing apoptosis of cancer cells by ROS produced by PDT, immunogenic cell death to provoke the maturation of dendritic cells, which in turn activate production of CD4+ T cells, CD8+T cells and memory T cells, as well as inhibiting heat shock protein (HSPs), STAT3 signal pathway and so on.

show abstract

CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells

Cited by 32 publications

References 31 publications

Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention

Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention

Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticulum chaperones

<p>Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles</p>

Contact Info

Product

Resources

About